Introduction {#S0001}
============

Interstitial lung disease (ILD) is characterized by diffuse pulmonary parenchyma, alveolar inflammation, and interstitial fibrosis. The incidence of ILD was 20--30% in patients with rheumatoid arthritis (RA) according to the study by Castelino et al.[@CIT0001] ILD commonly occurs as an extra-articular manifestation of severe RA,[@CIT0002] and results in high morbidity and mortality.[@CIT0003],[@CIT0004] Additionally, the prevalence of ILD has been confirmed to increase by 0.3--11% in RA treated with methotrexate (MTX),[@CIT0005],[@CIT0006] which serves as a reminder that more caution should be taken when using other disease-modifying drugs (DMARDs). Although TNF-I has been widely used in the past decades, its adverse effects on non-infectious complications (especially ILD) have not been well recognized and warrant investigation.

Initially, we presumed that ILD in patients with RA may benefit from TNF-I because TNF-α plays a pivotal role in the pathogenesis of ILD.[@CIT0007] A case report from the same period also indicated that TNF-1 has a positive effect on ILD.[@CIT0008] The results of clinical randomized controlled trials further emphasized that there is no difference compared with other DMARDs in terms of ILD. However, an ever-increasing incidence of adverse events has been reported since the first report of ILD induction by infliximab in 2002 buchong cankao wenxian. The randomized controlled trials performed thus far do not provide enough guidance. Therefore, we performed a systematic literature research and attempted to summarize the commonalities in order to better characterize the magnitude of this problem.

In this review, we discuss the risks of TNF-I use with respect to new onset of RA-ILD, the deterioration of RA-ILD, and the mortality of RA-ILD based on clinical cohort studies and case reports. We attempted to summarize the clinical characteristics of ILD adverse events, and to distinguish ILD secondary to TNF-I therapy from spontaneous ILD. Lastly, we hope to raise more awareness, enhance the diagnosis, improve the therapy, and fill the gaps in current knowledge.

Methods {#S0002}
=======

Search strategy {#S0002-S2001}
---------------

The PubMed, Embase, Ovid, Cochrane, China National Knowledge Infrastructure, and Wanfang databases were searched using the keywords "etanercept", "infliximab", "adalimumab", "golimumab", "certolizumab pegol", "tumour necrosis factor inhibitors", "anti-TNF", "biologic disease-modifying anti-rheumatic drugs", "lung diseases, interstitial", and "pulmonary fibrosis", for articles published up to November 2018 according to PRISMA guidelines. The relevant references of the selected articles were also hand searched to retrieve additional eligible articles.

Inclusion and exclusion criteria {#S0002-S2002}
--------------------------------

The studies included in this systematic review had to meet all of the following inclusion criteria: (1) case-control studies, cohort studies, clinical trials, and case reports; (2) Chest CT as used to diagnose ILD, RA was diagnosed according to American College of Rheumatology European Union Against Rheumatism classification criteria for RA (2010) (3) presenting enough information about RA-ILD, TNF-I, and the relationship between them; (4) investigating the risk factors of RA-ILD (age, sex, smoking, antibody seropositivity, and others); and (5)written in the English language. The exclusion criteria were as follows: (1) basic studies, mechanistic studies, review articles, guidelines, and meta-analysis; (2) duplicate data presented in multiple studies, unavailability of full-text articles, and lack of necessary data; (3) included patients less than18 years old or pregnant women, and (4) Except for the simple RA.

Data extraction and statistical analysis {#S0002-S2003}
----------------------------------------

Two authors (Huang and Lin) independently determined the eligible studies according to the aforementioned criteria, extracted the required information, and addressed any discrepancies through a discussion.

Statistical analysis {#S0002-S2004}
--------------------

Statistical analysis was carried out using Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA, USA) and IBM SPSS Statistics 20.0 (IBM Corporation, Armonk, NY, USA), Chi-square test was used for statistical analysis.

Results {#S0003}
=======

Literature search {#S0003-S2001}
-----------------

As shown in [Figure 1](#F0001){ref-type="fig"}, a total of 1506 articles were identified through the database searching. We scored 1304 studies after the removal of duplicates; 1182 articles not relevant to our topic were excluded out of the systematic review after reviewing the titles. The remaining 122 articles underwent detailed reading of abstracts, among which 78 articles were further excluded according to the inclusion and exclusion criteria. Because 9 of the remaining 44 articles were not available of full-text, it's a pity finally we only get 7 eligible articles (22,981 patients) and another 28 case reports (40 patients). All of the selected studies were published between 2002 and 2018. More details about the eligible articles are provided in [Table 1](#T0001){ref-type="table"}, and details about the case reports are shown in [Table 2](#T0002){ref-type="table"}. We performed a descriptive review rather than a meta-analysis owing to the significant heterogeneity and the limited data.Table 1Cohort studies that assessed TNF-I on ILD in rheumatoid arthritisReferenceYearStudy designResearch typeRegion/populationNumbersData originPopulationExperimental groupControl groupObjectiveConclusionDetorakis et al[@CIT0015]2017NAProspectiveGreece168NARATNF-INon-biologic agentsInvestigate the efficacy and safety of TNF-I compared to non-biologic DMARDs in RANo new-onset ILD or exacerbation of preexisting-ILD, especially in patients with TNF-I supporting the efficacy and favorable safety profile of this treatment in RA patientsDruce et al[@CIT0014]2017NARetrospectiveBritish352NARA-ILDRTXTNF-ICompared mortality in patients with RA-ILD who revived RTX or TNF-I as their first biologicPatients with RA-ILD who received rituximab had lower mortality rates compared to TNF-INakashita et al[@CIT0010]2016Observational studyRetrospectiveJapan62Single centerRA-ILDABATNF-IPossible effect of abatacept on the progression of ILD in RA patientsAbatacept might have a lower risk of worsening pre-existing ILD than TNF-IKoo et al[@CIT0013]2015NARetrospectiveBritish24NARA-ILDTNF (death)TNF-IEvaluate the impact on mortality of TNF-I treatment of RA-ILDLung complications can occur within months of initial anti-TNF treatment in older RA-ILD patients and TNF-I should be used with caution in these patientsCurtis et al[@CIT0012]2015CohortRetrospectiveAmerica13,795Data sourceRATNF-IADA, RTX and CTREvaluate ILD incidence and the exacerbation among users of abatacept, rituximab, and tocilizumab compared with anti-TNF agents in adult RA patientsNo significant differences in the risk of ILD and its related complications between RA patients receiving TNF-I and MOA agentsNakashita et al[@CIT0010]2014Case-controlRetrospectiveJapan163Single centerRATNF-INon-biologic agentAssess the risks of TNF-I for patients with ILDTNF-I have the potential risk of ILD events, particularly for patients with pre-existing ILDHerrinton et al[@CIT0009]2013CohortRetrospectiveAmerica8,417Kaiser permanent Northern CaliforniaAutoimmune disease (RA)ETA,INF and ADAMTXEvaluate the association of TNF-I with risks of ILD/PF among persons with the autoimmune disease compared with non-biologic therapyCompared to non-biologic therapies TNF-I does not associate with a diagnosis of ILD[^1] Table 2Case reports that assessed TNF-I on ILD in rheumatoid arthritis12344456777ReferencePeno-Green et al[@CIT0031]Vassalo et al[@CIT0032]Bargagli et al[@CIT0019]Ostor et al[@CIT0021]Ostor et al[@CIT0021]Ostor et al[@CIT0021]Chatterjee[@CIT0033]Hennum et al[@CIT0034]Ostor et al[@CIT0026]Ostor et al[@CIT0026]Ostor et al[@CIT0026]Year20022002200420042004200420062006200620062006Age5071706067758459496167SexFMFFMFFMFFMSmokingNAEx-smokerNonNANANAEx-smokerNANonNANACCP or RASeropositiveSeropositiveNANANANASeropositiveSeropositiveSeropositiveSeropositiveSeropositiveRA history53NA12433Longstanding632124Pulmonary historyNAPulmonary fibrosisPulmonary fibrosisAsymptomatic fibrosis alveolitisAsymptomatic fibrosis alveolitisAsymptomatic fibrosis alveolitisNo respiratory symptomsPF and nodularNo respiratory historyMild RA-associated pulmonary fibrosisNo respiratory symptomsSymptomsCough and dyspneaDyspnea and coughNABreathlessBreathlessBreathlessFever, breathless and coughDyspnea, cough, and low-grade feverDyspnea, cough, and night sweatsBreathless and dry coughDyspnea and coughOnset delay2 mon1 year15 month2nd3rd2nd2 wks after 2nd infusion1 wk after 1stShortly after the 3rd3 wks following 2nd3 wks after 3rdMTXYesYesNoNoNoNoNoYesNoNoNoType of TNF-IETAINFINFINFINFINFINFINFINFINFINFPulmonary historyNAPulmonary fibrosisPulmonary fibrosisAsymptomatic fibrosis alveolitisAsymptomatic fibrosis alveolitisAsymptomatic fibrosis alveolitisNo respiratory symptomsPF and nodularNo respiratory historyMild RA-associated pulmonary fibrosisNo respiratory symptomsOutcomeDeteriorateImprovedImprovedDeathDeathDeathDeteriorateDeathRecoveryDeathDeath778910101112131313ReferenceOstor et al[@CIT0026]Ostor et al[@CIT0026]Mori et al[@CIT0035]Villeneuve et al[@CIT0027]Lindsay et al[@CIT0036]Lindsay et al[@CIT0036]Schoe et al[@CIT0037]Huggett and Armstrong[@CIT0038]Kramer et al[@CIT0013]Kramer et al[@CIT0013]Kramer et al[@CIT0013]Year20062006200620062006200620062006200220022002Age6875667061646776636480SexFFFMFFMFFFFSmokingYesEx-smokerNANANAEx-smokerEx-smokerNonNANANACCP or RASeropositiveSeropositiveSeropositiveSeropositiveNASeronegativeSeropositiveSeropositiveSeropositiveSeronegativeSeropositiveRA history133512101143NANANAPulmonary historyPulmonary fibrosisPulmonary fibrosisNo respiratory symptomsNo respiratory historyPulmonary fibrosisCOPD but without pulmonary fibrosisNANo respiratory symptomsNANodularNASymptomsBreathless and dry coughBreathless, lethargy and dry coughFever, headache and hypoxiaDyspnea, fever, and fatigueBreathlessBreathlessHigh fever, cough and dyspneaBreathless and dyspneicDyspnea and hypoxemiaFever, breathless, dyspnea and hypoxemiaFever, dyspnea and hypoxemiaOnset delay3 wks after 3rd1 wk following 2nd1 wk after 3rd9 day after 3rd infusion6 wks (12 injections)3 wks (6 injections)12 wks10 wksSoon after 3rd infusion1 wk after 3rd infusion3 wks after 3rd infusionMTXNoNoYesYesYesYesYesYesYesYesYesType of TNF-IINFINFINFINFETAETAADAADAINFINFINFPulmonary historyPulmonary fibrosisPulmonary fibrosisNo respiratory symptomsNo respiratory historyPulmonary fibrosisCOPD but without pulmonary fibrosisNANo respiratory symptomsNANodularNAOutcomeDeathDeathRecoveryRecoveryDeathRecoveryDeteriorateDeathRecoveryRecoveryRecovery1415161617171718192021ReferenceCourtney et al[@CIT0039]Hagiwara et al[@CIT0040]Tournadre et al[@CIT0041]Tournadre et al[@CIT0041]Antoniou et al[@CIT0020]Antoniou et al[@CIT0020]Antoniou et al[@CIT0020]Taki et al[@CIT0042]Pearce et al[@CIT0043]Yamazaki et al[@CIT0044]Komiya et al[@CIT0045]Year20062007200720072007200720072009201220102011Age7270425262647074716478SexFFMMMMMFFFMSmokingNAEx-smokerNonYesEx-smokerYesEx-smokerNANonNANACCP or RANASeropositiveSeropositiveSeropositiveSeropositiveSeropositiveSeropositiveSeronegativeSeropositiveSeropositiveSeropositiveRA historylongstanding61251025NA81818Pulmonary historyNo respiratory historyAsymptomatic ILDNo respiratory symptomsPulmonary fibrosisPulmonary fibrosisRheumatoid pulmonary historyPulmonary historyPulmonary fibrosisNo respiratory historyNo respiratory historyNo respiratory historySymptomsDyspnea, hypoxia, and feverBreathlessExertional dyspneaFever and dyspneaDyspnea, coughDyspnea, coughDyspnea, coughSevere dyspneaBreathless and dry coughDry coughFever and coughOnset delay4 wks after 3rd infusion8 wks36 wks4 wks1 y1 y1 ySoon after 2nd4 wks20 wksA monthMTXYesYesYesYesNoYesYesNoYesYesYesType of TNF-IINFETAETAETAINFINFINFINFCerADAADAPulmonary historyNo respiratory historyAsymptomatic ILDNo respiratory symptomsPulmonary fibrosisPulmonary fibrosisRheumatoid pulmonary historyPulmonary historyPulmonary fibrosisNo respiratory historyNo respiratory historyNo respiratory historyOutcomeDeathStableRecoveryStableImprovedImprovedImprovedRecoveryDeteriorateRecoveryRecovery22232425262728ReferenceCho et al[@CIT0046]Millar et al[@CIT0047]Lager et al[@CIT0048]Glaspole et al[@CIT0049]Dias et al[@CIT0050]Migita et al[@CIT0030]Watad et al[@CIT0051]Year2012201220132013201320172015Age36677266626863SexFMFFFFFSmokingNonNAEx-smokerNonNAYesNonCCP or RANASeropositiveSeropositiveSeropositiveNANANARA history12344335201510Pulmonary historyNAMTX-induced pneumonitis historyNANANo respiratory historyPulmonary fibrosisNASymptomsCoughShort of breathDry cough and shiveringBreathless and coughDry cough, dyspnea and feverBreathless, dyspnea and dry coughDry cough and dyspneaOnset delayNANA (he failed to Cer until 12 wks)8 wks12 wks1 wk after 2nd3 wks16 wksMTXYesYesYesYesYesNoYesType of TNF-IETACerCerCerADACerETAPulmonary historyNAMTX-induced pneumonitis historyNANANo respiratory historyPulmonary fibrosisNAOutcomeDeteriorateDeathStableDeathRecoveryRecoveryDeteriorate[^2] Figure 1Search parameters and strategies of literature review.

Controversy and consensus in large-sample studies {#S0003-S2002}
-------------------------------------------------

As shown in [Table 1](#T0001){ref-type="table"}, Herrinton et al[@CIT0009] provided evidence that TNF-I does not increase the incidence of ILD in autoimmune diseases, mainly in RA. However, Nakashita et al[@CIT0010] suggested that TNF-I has the potential risk of inducing ILD and might exacerbate pre-existing ILD compared with non-TNF-I biological therapy. Moreover, their further study[@CIT0011] emphasized that TNF-I was less effective than abatacept in patients with pre-existing ILD. In the same year, Curtis et al[@CIT0012] reported that no significant risks of ILD and related complications were observed with TNF-I when compared with T-cell, B-cell, and interleukin (IL)-6 inhibitors. In a small-sample study, Koo et al[@CIT0013] emphasized that a potential risk of mortality existed in older patients with RA-ILD within months of the initial TNF-I therapy. In 2017, Druce et al[@CIT0014] hypothesized that patients with RA-ILD using TNF-I had a higher mortality rate than patients using rituximab. Additionally, Detorakis et al[@CIT0015] compared TNF-I with MTX and then provided supporting evidence for the efficacy and safety of TNF-I according to high-resolution computed tomography (HRCT) evaluation and pulmonary function tests [@CIT0015]and compared TNF-I with MTX. In short, previous studies demonstrated the tendency that ILD might not benefit from TNF-I therapy.

Noteworthy differences in case reports {#S0003-S2003}
--------------------------------------

As depicted in [Table 3](#T0003){ref-type="table"}, we found that ILD adverse events after TNF-I therapy accounted for 87.5% of the retrieved cases. A 68.57% rate of positivity to rheumatoid factor or anti-cyclic citrullinated peptide antibody was mentioned in the known case reports, and most patients presented an invasive disease. Initially, we speculated that age, sex, RA history, pulmonary history, use of MTX, and the different types of TNF-I led to different outcomes. After the statistical analysis (chi-square test) of retrieved cases, we conjectured that TNF-I is beneficial or harmful to ILD depending on the history of RA and sex (*p*\<0.05), rather than age, use of MTX, and other factors. A female preponderance (74.29%) was observed in the spontaneous ILD adverse events, whereas patients treated with TNF-I included more men. Although all ILD benefits were derived from infliximab antibodies, the performance of infliximab in ILD adverse events showed no significant differences compared with other TNF-I drugs.Therefore, more attention should be paid to pulmonary symptoms when TNF-I is prescribed for long-term use in female patients with RA.Table 3Noteworthy differences in case reportsILD improved (N=5)ILD induced or deteriorate (N=35)*p*-ValueAge67.4±3.56 years65.23±10.16 years0.642Gender (female) (number/ratio)1(25.71%)26(74.29)0.031History of RA5±3.56 years15±4.4 years0.000Used of MTX (number/ratio)3(60%)24(68.37%)1.00Onset of disease1 yearINF 2--3 wks after 2--3 doses--Using INF (number/ratio)5(100%)17(48.57%)0.053CCP or RF positive (number/ratio)4(80%)24(68.57%)--[^3]

Possible decisive factors for different outcomes {#S0003-S2004}
------------------------------------------------

The above results showed that most patients experienced ILD adverse events; however, the outcome was variable. We performed a sub-group analysis (death and survival) of ILD adverse events to explore the decisive factors. The results in [Table 4](#T0004){ref-type="table"} indicate that deaths accounted for 40% of the ILD adverse event cases. After the analysis of these results with the chi-square test, significant differences were observed in age, pre-existing lung disease, use of antibiotics, and combination treatment with azathioprine (*p*\<0.05). Patients who died were older (66 vs 64 years) and had a higher use of antibiotics (77% vs 29%). In addition, the combination of azathioprine was positively associated with death. Although the use of MTX might be a risk factor of ILD adverse events, our results showed that the combination of MTX with infliximab probably did not affect ILD. In addition to the quantifiable results, we speculated that patients who died had a more urgent and severe condition based on the median episode delay. Therefore, early detection and precise treatment may be key factors in determining the chances of survival when an ILD adverse event occurs.Table 4Decisive factors of patients receiving TNF-I therapy for different outcomesDeath (N=14)Survivors (N=21)*p*-ValueAge (years)66.93±5.5964.10±11.960.416Gender (female)10 (71%)16(76%)1.000Smoker2/5(40%)6/10(60%)0.608CombinationINF + MTX7(50%)17(81%)0.073INF + AZA6(43%)1(5%)0.010History of RA15.15±12.8314.13±10.300.796Median onset delay3 wks8 wks--Pre-existing lung disease11/13 (79%)6/14(47%)0.046Joint symptom Remission6/8 (75%)13/14 (93%)0.527Causes of deathPulmonary deteriorate: 8 MSOF:1----Use of antibiotics10(71%)6(29%)0.018Without use of prednisolone2NA--[^4]

Predictors of the probability of onset {#S0003-S2005}
--------------------------------------

The aforementioned data indicated that timely diagnosis and treatment of ILD might affect outcomes. Therefore, we attempted to identify those predictive features to allow early detection. As shown in [Figure 2](#F0002){ref-type="fig"}, infliximab dominance was obvious in both the survival and death groups, whereas the proportion of adalimumab use was low in the death group. [Table 2](#T0002){ref-type="table"} demonstrates that the time to death ranged from a few days to 36 weeks; however, [Figure 2C](#F0002){ref-type="fig"} shows significant differences between the survivor and death groups in patients treated with etanercept (*p*\<0.05). Like acute ILD, the most common clinical manifestations in ILD adverse events cases were shortness of breath and sudden dyspnoea (n=31), followed by non-productive cough (n=17). Further, approximately 10 patients were hospitalized with fever. As HRCT is the cornerstone of ILD diagnosis, we searched for related imaging features. The most common patterns were ground glass and reticulation, which were present in more than half of the patients and tended to be sub-pleural and basilar in distribution ([Table 2](#T0002){ref-type="table"}). Surprisingly, the presence of a distinct honeycomb pattern seems to be relatively rare in ILD adverse events. Therefore, we conclude that patients with typical or atypical disease presenting with the ground-glass pattern after a few weeks of the last infusion are highly suspicious of having ILD.Figure 2Noteworthy differences in case reports. (**A**) Percentage of different types of biological agents in survivor group; (**B**) Percentage of different types of biological agents in death group; (**C**) Comparison of onset time of different types of biological. \*\*\**p*\<0.05.**Abbreviations:** ADA, adalimumab; Cer, certolizumab pegol; INF, infliximab; ILD, interstitial lung disease; ETA, etanercept; ns, not significant.

Management of ILD adverse events {#S0003-S2006}
--------------------------------

[Table 4](#T0004){ref-type="table"} indicates that inappropriate use of antibiotics might be associated with death. Thus, there is a need to improve the therapy. Some patients recovered after the timely withdrawal of TNF-I and supplementation with high-dose corticosteroids in the acute period, with tapering to lower doses as necessary depending on the condition. However, the empirical use of broad-spectrum antibiotics and increased dose of antibiotics achieved limited effects. In addition, some patients benefited from home oxygen therapy.

Discussion {#S0004}
==========

Although a better understanding of the pathogenesis of RA and the development of therapies had improved the clinical outcomes in the past decades, the incidence of extra-articular manifestations in patients with RA showed no decrease.[@CIT0002] A study also indicated that pulmonary involvement occurs in 60--80% patients,[@CIT0016] and ILD particularly greatly affects the morbidity and mortality of RA.[@CIT0003] Substantial health-care use and costs were needed with the increasing prevalence of RA- ILD.[@CIT0003] Since drug-induced ILD is better than idiopathic ILD in prognosis,[@CIT0017] there is an urgent need to better identify and avoid the risk factors. As TNF-I is widely used in patients with RA, the safety of TNF-I for ILD needs to be established. In addition to the aforementioned problems, TNF-I-induced ILD not only increases the comorbidities and the mortality rate, but also adds to the difficulty of diagnosis, which, in turn, limits the use of therapeutic drugs. Therefore, we aimed to raise awareness and improve the therapy by evaluating the correlation between TNF-I and ILD in RA.

Previous studies about the relationship between TNF-I and ILD showed controversial results. As TNF-α is known to play a key role in the pathogenesis of ILD,[@CIT0018] earlier case reports considered that TNF-I had a positive effect on ILD. In 2004, Bargagli et al[@CIT0016] observed the improvement of pulmonary function with 15 months of infliximab treatment, and another study published in 2007 suggested that infliximab might stabilize the progression of ILD in RA.[@CIT0020] Clinical results indicated that TNF-I has not increased the incidence of ILD in patients with RA compared with non-biologic therapies[@CIT0009] or alternative mechanism-of-action agents.[@CIT0012] However, ever-increasing cases have been reported after the case of fatal exacerbation of RA-ILD in a patient treated with infliximab in 2004.[@CIT0021] An analysis[@CIT0022] of 122 cases caught our attention owing to the high incidence of ILD after TNF-I (29%), which is 50 times of that reported in a study using post-marketing surveillance data from Japan (0.6%).[@CIT0023] A later study demonstrated that the proportion of deaths attributable to RA-ILD was higher in patients treated with TNF-I than in those treated with rituximab,[@CIT0014] consistent with a cohort study on rituximab.[@CIT0024]

On the basis of the results, we read the articles and case reports in detail, and found that the controversial results were due to the differences in the population selection, control group, observation period, diagnosis of ILD, and outcome indicators. The current incidence is probably underestimated owing to the rarity of the disease, the short observation period of randomized controlled trials, and the diagnostic methods used to confirm TNF-I associated ILD. The criteria for diagnosing ILD adverse events were as follows: ILD adverse events occurring with an acute or sub-acute lung manifestation shortly after TNF-I infusion with or without remission of articular manifestations, and other related diseases can be excluded on the basis of consistent radiological findings. Notably, patients always do not respond to empiric antibiotic therapy, but symptoms improve when TNF-I is removed. Although the usual interstitial pneumonia pattern accounted for the majority of RA-ILD cases, both pathologically and radiologically,[@CIT0025] the non-specific interstitial pneumonia pattern was the most common imaging type in TNF-I-associated ILD adverse events. These imaging features indicate an acute onset of ILD that enhances the confidence in the diagnosis. Although azathioprine is the recommended drug for the treatment of RA-ILD, a study[@CIT0026] highlighted the risk of infliximab in combination with azathioprine.

Additionally, the fact that nearly 40% of patients died indicates that detection and precise therapy should not be delayed. Considering the risks and unforeseen results, we believe that rituximab and abatacept might be better choices than TNF-I agents in patients with pre-existing ILD. Once TNF-I is prescribed to patients with RA, more caution should be taken, especially in older patients with a longer RA history or a rheumatoid-associated pulmonary disease. Respiratory symptoms should be evaluated at follow-up. Pulmonary auscultation is recommended as a routine test. Moreover, high-resolution computed tomography of the lung should be conducted as necessary in the first few infusions of TNF-I. When a patient with RA complained of dyspnoea and dry cough without infectious evidence, withdrawing TNF-I and adding prednisolone are recommended. In the presence of fever, night sweats, and other atypical manifestations, ILD should be distinguished from infectious disease as soon as possible. Hence, more mechanisms should be explored and more randomized controlled studies are needed.

Despite the elucidation of the clinical characteristics of ILD adverse events, the pathogenesis remains unclear. Initially, researchers were reluctant to attribute the lung toxicity to TNF-I itself when TNF-I (mainly infliximab) was as a step-up therapy or used in combination with MTX or azathioprine. Perez-Alvarez et al[@CIT0022] postulated that TNF-I potentiates the lung toxicity of MTX, which was then confirmed by an MTX study[@CIT0027] and an azathioprine study.[@CIT0028] With the ever-increasing use of TNF-I, an increasing incidence of pneumonia toxicity arises. Researchers who considered the status of RA suspected that TNF-I broke the balance (Th1 and Th2, TNF, interferon-γ, and IL-1) and attributed the adverse effects to inflammatory-mediated pathways.[@CIT0029] As another interesting interpretation, Migita et al[@CIT0030] speculated that acute exacerbation of RA-ILD treated with certolizumab was due to NLRP3 inflammation activation. Although we found that the onset of ILD adverse events occurred soon after the last infusion, we supposed that the heterogeneous (mouse) of TNF-I might cause allergic reactions and induce ILD indirectly. The separate analysis of articular and lung manifestations suggested that fast remission might make patients poorly tolerant, with pneumonia as one of the manifestations.

Even with the available evidence, it remains difficult to confirm whether TNF-I is beneficial or harmful to ILD owing to the rarity of the disease. However, the ever-increasing case reports serve as a reminder that TNF-I might induce more severe symptoms, even death. Evidence showing that some patients with RA developed ILD adverse events indicates that doctors should pay more attention during the first few weeks when introducing TNF-I, especially in old female RA patients with pre-existing ILD. Once ILD adverse events occur, precise and timely therapy could be life saving.

Limitations {#S0005}
===========

We acknowledge that the reported risks of TNF-I-induced ILD varied depending on the study population, control group, drug combinations, outcome indicators, and research duration. Moreover, the heterogeneity of ILD (the slice differences between spontaneous and drug-induced ILD) makes it a complex task to interpret the association or causality between TNF-I and ILD. Inevitably, our study has several limitations. First, we attempted to incorporate cohort studies and case reports to increase the power; however, publication bias from the collected articles cannot be excluded. Second, as ILD is a progressive disease, with the first diagnosis occurring after the true incidence, the results of ILD progression might coincide with the TNF-I infusion. Third, because we are overwhelmed with the concern about the occurrence of ILD, the benefit of TNF-I in delaying ILD might have been neglected. Lastly, the assessment of causality is not completely accurate without the mechanisms.

Conclusion {#S0006}
==========

In summary, patients with RA might not benefit from TNF-I in terms of ILD, and more attention should be paid on TNF-I-associated ILD. Early detection and precise treatment are key factors in determining the chances of survival when an ILD adverse event occurs. A prospective study is needed to establish the association or causality between TNF-I and ILD adverse events. The more mechanisms are known, the more therapies will be developed and the more benefits will be achieved.
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[^1]: **Abbreviations:** NA, unknown; RTX, rituximab; CTR, tocilizumab; ADA, adalimumab; ABA, abatacept TNF-I, tumor necrosis factor inhibitor; MTX, methotrexate; ILD, interstitial lung disease; PF, pulmonary failure; MOA, alternate mechanisms of action; RA, rheumatoid arthritis; DMARD, disease-modifying drugs; ETA, etanercept; INF, infliximab.

[^2]: **Abbreviations:** F, female; M, male; NA, unknown;  ADA, adalimumab; ABA, abatacept; Cer, certolizumab pegol; INF, infliximab; ETA, etanercept. wk(s), week(s); TNF-I, tumor necrosis factor inhibitor; MTX, methotrexate; ILD, interstitial lung disease; PF, pulmonary fibrosis; MOA, alternate mechanisms of actions; RA, rheumatoid arthritis; CCP, cyclic citrullinated peptides; COPD, chronic obstructive pulmonary disease.

[^3]: **Abbreviation:** ILD, interstitial lung disease; RA, rheumatoid arthritis; MTX, methotrexate; INF, infliximab; CCP cyclic citrullinated peptides; RF, rheumatoid factor.

[^4]: **Abbreviations:** INF, infliximab; AZA, azathioprine; MTX, methotrexate; RA, rheumatoid arthritis; NA, unknown; MSOF, multiple systems organ failure; TNF-I, tumor necrosis factor inhibitor.
